Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat

Table 4

Areas under the curve of gliclazide serum concentrations (AUC), apparent volume of distribution (Vd), and blood glucose level (mmol/L) 240 seconds after and before intra-arterial gliclazide injection.

Groups	Mean ± SD
	AUC (𝜇g * s * mL^−1)	Vd (mL)	Glucose level (mmol/L)
			Before gliclazide	After gliclazide (240 s)
Group 1 healthy animals: gliclazide; 𝑛=6	4020.43±456.42	219.73±13.47	7.01±0.3	9.55±0.34^∗∗
Group 2 healthy animals: gliclazide + DA; 𝑛=6	3931.02±1790.13	1077.19±83.43^∗	8.11±0.60	9.53±0.46^∗∗
Group 3 diabetic animals: gliclazide; 𝑛=6	2150.16±1472.50	970.15±79.97^#	29.04±4.20	30.95±3.86
Group 4 diabetic animals: gliclazide + DA; 𝑛=6	1678.7±415.21^××	648.42±203.65^××	32.50±5.75	34.3±7.44
Healthy animals	/	/	7.7±0.3	8.7±0.35
Diabetic animals	/	/	28.83±2.23	29.33±2.19
Healthy animals with DA pretreatment	/	/	6.93±0.6	7.45±1.02
Diabetic animals with DA pretreatment	/	/	33.58±4.02	29.7±4.30

∗Group 2 versus Group 1, 𝑃≤0.05; ^××Group 4 versus Group 1, 𝑃≤0.05; ^#Group 3 versus Group 1, 𝑃≤0.05; **glucose level before versus after gliclazide, 𝑃≤0.05.